Skip to Main Content

Sabine Mueller


Pediatric neurologist
Pediatric neuro-oncologist

Dr. Sabine Mueller is a pediatric neuro-oncologist who specializes in caring for children with brain tumors and related genetic syndromes. Before completing medical school, she worked as a scientist, director of genomics and project leader for a brain tumor program at AGY Therapeutics, a biotechnology company in South San Francisco.

In her research, Mueller studies treatments for children with brain tumors, looking especially at improving long-term cognitive outcomes.

Mueller earned her medical degree at the Universität Hamburg Faculty of Medicine and earned a doctorate in biochemistry and molecular biology in collaboration with AGY. After a residency in pediatrics at Massachusetts General Hospital, she completed a fellowship in pediatric oncology at UCSF.

  • Education

    Universität Hamburg School of Medicine, MD, 2005

  • Residencies

    Massachusetts General Hospital, Pediatrics, 2006

  • Fellowships

    UCSF, Pediatric Neurology, 2009

    UCSF, Neuro-Oncology, 2010

Where I see patients (3)

    Decorative Caduceus

    BGB-290 and Temozolomide in Treating Isocitrate Dehydrogenase (IDH)1/2-Mutant Grade I-IV Glioma...

    Events occurring on or after treatment on Day 1 will be classified using the Common Terminology Criteria for Adverse Events (CTCAE) v5.0. Adverse events leading to treatment discontinuation will be listed.


    More about this study
    Decorative Caduceus

    ONC206 for Treatment of Newly Diagnosed, or Recurrent Diffuse Midline Gliomas, and Other Recurr...

    A DLT is defined as a treatment-related adverse event (AE) or abnormal laboratory value that occurs in the first cycle of treatment (Cycle 1 for Arm A and D; Cycle 0 for Arm B and C), meets criteria for DLT as outlined below and i...


    More about this study
    Decorative Caduceus

    Trametinib and Everolimus for the Treatment of Pediatric and Young Adult Patients With Recurren...

    We will employ the Bayesian optimal interval (BOIN) design to find the MTD for both continuous and intermittent dosing schedules. The BOIN design is implemented in a simple way similar to the traditional 3+3 design, but is more fl...


    More about this study
    Decorative Caduceus

    Modified Measles Virus (MV-NIS) for Children and Young Adults With Recurrent Medulloblastoma or...

    The safety of the modified measles virus will be assessed by monitoring for adverse events. Subjects will be monitored for adverse events via scheduled laboratory assessments, vital sign measurements, and physical examinations. Th...


    More about this study
    See all clinical trials

    Staff superheroes

    It’s a bird. It’s a plane. It’s a window washer! Dressed as a superhero to clean and brighten your day.